Previous 10 | Next 10 |
Thinly traded nano cap Genocea Biosciences ( GNCA ) is up 22% out of the gate this morning following its announcement that the first patients have been dosed in a Phase 1/2a clinical trial evaluating neoantigen cancer vaccine candidate GEN-009. More news on: Genocea Bioscie...
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the dosing of the first patients in its Phase 1/2a clinical trial testing the safety, immunogenicity,...
CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the hiring of industry veteran Girish Aakalu, Ph.D., as its new Chief Business Officer. In this role,...
ATLAS™-identified “inhibitory” neoantigens promote tumor growth in mouse model ATLAS platform continues to differentiate versus in silico methods for true neoantigen identification CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Genocea Bi...
Genocea Biosciences, Inc. (GNCA) Q3 2018 Earnings Conference Call November 1, 2018, 09:00 ET Executives Paul Arndt - Head of IR and MD, Communications, LifeSci Advisors William Clark - President, CEO & Director Jessica Flechtner - Chief Scientific Officer Tom Davis - Chief ...
Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial enrolling patients Presenting novel findings at upcoming SITC conference Conference call today at 9:00 am ET CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharm...
CAMBRIDGE, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, November 1, 2018 at 9:00...
NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Genocea Biosciences, Inc. (NASDAQ:GNCA), Retail Properties of America,...
Posters showcase ability of ATLAS™ platform to identify neoantigens for inclusion in and exclusion from personalized immunotherapies CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing persona...
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced two additions to its leadership team: Thomas Davis, M.D. as Chief Medical Officer and Derek Meisner, ...
News, Short Squeeze, Breakout and More Instantly...
Genocea Biosciences Inc. Company Name:
GNCA Stock Symbol:
NASDAQ Market:
Genocea Biosciences Inc Ordinary Shares (GNCA) is expected to report for Q4 2022